UBS O'Connor’s Redhill Biopharma RDHL Stock Holding History

UBS O'Connor’s Portfolio RDHL Stock Details RDHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-83	Closed	-$586K	–	353
2019 Q3	$586K	Buy	+83	New	+$604K	0.02%	231

Other funds holding RDHL

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Claret Asset Management Montreal, Quebec, Canada $837M AUM 25.51% 1-Year Est. Return

UBS O'Connor's RDHL Position: Q4 2019 in Review

UBS O'Connor sold out of Redhill Biopharma (RDHL) in Q4 2019, closing a stake of 83 shares — an estimated $586K sold.

UBS O'Connor first reported a position in RDHL in Q3 2019 and held it in 1 quarter. The position peaked at $586K in Q3 2019. 42 funds tracked by Wall St. Rank hold RDHL as of Q4 2019.

UBS O'Connor reported no remaining Redhill Biopharma position as of Q4 2019 after selling out during the quarter.
UBS O'Connor sold 83 Redhill Biopharma shares in Q4 2019, an estimated $586K.
UBS O'Connor first reported a position in Redhill Biopharma in Q3 2019 and held it in 1 quarter.
UBS O'Connor's Redhill Biopharma position peaked at $586K in Q3 2019.
42 funds tracked by Wall St. Rank held Redhill Biopharma as of Q4 2019.

Based on UBS O'Connor's 13F filing for Q4 2019, filed 14 Feb 2020.